Published in Nat Immunol on December 01, 2013
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature (2014) 5.34
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. Nat Med (2016) 2.22
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature (2016) 1.52
HTLV-1 bZIP Factor Enhances T-cell Proliferation by Impeding the Suppressive Signaling of Co-inhibitory Receptors. PLoS Pathog (2017) 1.38
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. Immunity (2016) 1.27
Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. Eur J Radiol (2015) 1.07
Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 1.04
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. Theranostics (2016) 1.03
Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol (2015) 1.02
Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet (2015) 1.01
Pembrolizumab. J Immunother Cancer (2015) 0.99
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. J Hematol Oncol (2017) 0.99
Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. Shock (2015) 0.97
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma. Exp Hematol Oncol (2015) 0.95
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. CPT Pharmacometrics Syst Pharmacol (2016) 0.93
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Unique human immune signature of Ebola virus disease in Guinea. Nature (2016) 0.92
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther (2014) 0.91
Novel therapeutic strategies for multiple myeloma. Exp Hematol (2015) 0.91
HIV-1 latency: an update of molecular mechanisms and therapeutic strategies. Viruses (2014) 0.89
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother (2016) 0.89
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.88
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun (2016) 0.86
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model. Proc Natl Acad Sci U S A (2016) 0.85
Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res (2016) 0.84
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med (2016) 0.84
Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther (2015) 0.84
CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. PLoS Pathog (2016) 0.83
Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci (2017) 0.82
Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact. Cancer Sci (2015) 0.82
TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. PLoS Pathog (2016) 0.82
Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv (2015) 0.82
Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol (2015) 0.81
PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol (2015) 0.81
PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother (2014) 0.80
PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology (2015) 0.80
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. PLoS One (2015) 0.79
PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathog (2015) 0.79
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer (2016) 0.79
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Int J Clin Oncol (2016) 0.79
Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders. Front Cell Neurosci (2014) 0.79
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. Medicine (Baltimore) (2016) 0.78
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging (2017) 0.78
Lipid and Protein Co-Regulation of PI3K Effectors Akt and Itk in Lymphocytes. Front Immunol (2015) 0.78
Melanoma: oncogenic drivers and the immune system. Ann Transl Med (2015) 0.78
Immune based therapy for melanoma. Indian J Med Res (2016) 0.78
Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens. J Immunol (2015) 0.78
CD8(+) T cells in human autoimmune arthritis: the unusual suspects. Nat Rev Rheumatol (2016) 0.78
Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediators Inflamm (2017) 0.78
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget (2016) 0.77
Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer (2016) 0.77
Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci Rep (2016) 0.77
Narrowing the Gap: Preserving Repertoire Diversity Despite Clonal Selection during the CD4 T Cell Response. Front Immunol (2015) 0.77
Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. Oncoimmunology (2016) 0.77
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint. Oncotarget (2016) 0.77
Basics of PD-1 in self-tolerance, infection, and cancer immunity. Int J Clin Oncol (2016) 0.77
Imaging of Cell-Cell Communication in a Vertical Orientation Reveals High-Resolution Structure of Immunological Synapse and Novel PD-1 Dynamics. J Immunol (2015) 0.77
The multiple pathways to autoimmunity. Nat Immunol (2017) 0.76
Features of Memory-Like and PD-1(+) Human NK Cell Subsets. Front Immunol (2016) 0.76
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies. Breast Cancer Res Treat (2016) 0.76
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. J Transl Med (2016) 0.76
Anti-PD-L1 peptide improves survival in sepsis. J Surg Res (2016) 0.76
High-resolution crystal structure of the therapeutic antibody pembrolizumab bound to the human PD-1. Sci Rep (2016) 0.76
Roles of PD-1, Tim-3 and CTLA-4 in immunoregulation in regulatory T cells among patients with sepsis. Int J Clin Exp Med (2015) 0.75
miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget (2016) 0.75
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget (2017) 0.75
An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Res (2016) 0.75
Immunomodulatory drugs II: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets (2015) 0.75
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci U S A (2017) 0.75
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res (2017) 0.75
Acute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor Function. PLoS Pathog (2016) 0.75
Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology (2016) 0.75
A Novel PD-L1-targeting Antagonistic DNA Aptamer With Antitumor Effects. Mol Ther Nucleic Acids (2016) 0.75
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. Int J Oncol (2016) 0.75
Human NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 Receptor. Front Immunol (2016) 0.75
Adaptor protein DOK3 promotes plasma cell differentiation by regulating the expression of programmed cell death 1 ligands. Proc Natl Acad Sci U S A (2014) 0.75
Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma. Biomaterials (2016) 0.75
Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight (2016) 0.75
Programmed cell death 1 correlates with the occurrence and development of MG63 osteosarcoma. Oncol Lett (2016) 0.75
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Ann Transl Med (2016) 0.75
Attenuation of lymphocyte immune responses during Mycobacterium avium complex-induced lung disease due to increasing expression of programmed death-1 on lymphocytes. Sci Rep (2017) 0.75
Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma. Oncoimmunology (2016) 0.75
IL-32 induces indoleamine 2,3-dioxygenase(+)CD1c(+) dendritic cells and indoleamine 2,3-dioxygenase(+)CD163(+) macrophages: Relevance to mycosis fungoides progression. Oncoimmunology (2016) 0.75
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget (2016) 0.75
Blockade of PD-1 Signaling Enhances Th2 Cell Responses and Aggravates Liver Immunopathology in Mice with Schistosomiasis japonica. PLoS Negl Trop Dis (2016) 0.75
Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncoimmunology (2016) 0.75
Destabilizing the autoinhibitory conformation of Zap70 induces up-regulation of inhibitory receptors and T cell unresponsiveness. J Exp Med (2017) 0.75
Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. Cancer Immunol Immunother (2016) 0.75
Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. Clin Exp Immunol (2017) 0.75
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway. Onco Targets Ther (2017) 0.75
PD-1 Suppresses Development of Humoral Responses That Protect against Tn-Bearing Tumors. Cancer Immunol Res (2016) 0.75
Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight (2017) 0.75
Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush. Exp Eye Res (2015) 0.75
Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics (2017) 0.75
Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug Des Devel Ther (2017) 0.75
Metabolic shift induced by systemic activation of T cells in PD-1-deficient mice perturbs brain monoamines and emotional behavior. Nat Immunol (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature (1992) 16.46
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A (1993) 10.82
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 8.86
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J Immunol (2007) 5.14
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity (2012) 4.98
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med (2011) 4.83
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
TGF-beta: a master of all T cell trades. Cell (2008) 4.60
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol (2004) 4.58
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med (2011) 4.50
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol (1998) 4.14
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol (2010) 3.51
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med (2012) 3.37
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A (2001) 3.32
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol (1999) 2.77
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
T-Independent immune response: new aspects of B cell biology. Science (2000) 2.63
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol (2001) 2.57
Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4+ T cell-B cell collaboration. J Immunol (2007) 2.56
Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev (2011) 2.54
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity (2011) 2.49
Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature (2001) 2.42
Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol (2011) 2.27
Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 2.21
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol (2012) 2.17
The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science (2012) 2.06
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. Immunity (1997) 1.94
NFATc1 regulates PD-1 expression upon T cell activation. J Immunol (2008) 1.81
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity (2004) 1.70
Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes. Int Immunol (1996) 1.68
Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens (2003) 1.66
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 1.64
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat Immunol (2013) 1.57
Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A (2008) 1.55
STAT5 protein negatively regulates T follicular helper (Tfh) cell generation and function. J Biol Chem (2012) 1.51
Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3. J Immunol (2002) 1.41
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol (2009) 1.31
Treg and CTLA-4: two intertwining pathways to immune tolerance. J Autoimmun (2013) 1.18
PD-1-mediated suppression of IL-2 production induces CD8+ T cell anergy in vivo. J Immunol (2009) 1.14
PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia. Proc Natl Acad Sci U S A (2009) 1.14
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A (1997) 1.14
Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. Clin Exp Immunol (2003) 1.12
Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog (1996) 1.09
Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. J Immunother (2011) 1.08
PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol (2010) 1.02
Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens. J Immunol (2011) 0.97
TGF-beta and CD4+CD25+ regulatory T cells. Front Biosci (2006) 0.96
Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b-/-Pdcd1-/- mice. J Exp Med (2005) 0.93
PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc Natl Acad Sci U S A (2008) 0.89
PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun (2005) 0.88
Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. Proc Natl Acad Sci U S A (2013) 0.83
Non-specific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects. Int J Cardiol (2006) 0.82
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci U S A (2004) 5.93
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05
Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med (2011) 4.83
Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science (2009) 4.80
Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int Immunol (2002) 4.66
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol (2005) 4.01
Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev (2004) 3.95
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol (2002) 3.78
Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol (2002) 3.75
Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med (2007) 3.70
AID mutant analyses indicate requirement for class-switch-specific cofactors. Nat Immunol (2003) 3.69
Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. Immunity (2008) 3.64
Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature (2002) 3.60
Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science (2002) 3.58
Constitutive expression of AID leads to tumorigenesis. J Exp Med (2003) 3.16
AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science (2002) 3.09
PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med (2003) 3.05
Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep (2008) 3.03
Regulation of alphabeta/gammadelta T cell lineage commitment and peripheral T cell responses by Notch/RBP-J signaling. Immunity (2004) 3.01
Uracil DNA glycosylase activity is dispensable for immunoglobulin class switch. Science (2004) 2.93
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
AID is required for germinal center-derived lymphomagenesis. Nat Genet (2007) 2.79
Forebrain ependymal cells are Notch-dependent and generate neuroblasts and astrocytes after stroke. Nat Neurosci (2009) 2.74
Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc Natl Acad Sci U S A (2004) 2.69
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med (2003) 2.66
Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med (2003) 2.65
Intestinal IgA synthesis: regulation of front-line body defences. Nat Rev Immunol (2003) 2.62
B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity (2004) 2.60
Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 2.57
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A (2005) 2.49
The AID enzyme induces class switch recombination in fibroblasts. Nature (2002) 2.28
Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J Exp Med (2002) 2.18
Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol (2003) 2.16
Regulation of B1 cell migration by signals through Toll-like receptors. J Exp Med (2006) 2.11
Separate domains of AID are required for somatic hypermutation and class-switch recombination. Nat Immunol (2004) 2.06
The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science (2012) 2.06
Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity (2003) 2.03
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. Proc Natl Acad Sci U S A (2008) 2.03
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol (2004) 2.02
Regulation of lymphocyte development by Notch signaling. Nat Immunol (2007) 1.96
New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol (2002) 1.92
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev Biol (2006) 1.80
Discovery of activation-induced cytidine deaminase, the engraver of antibody memory. Adv Immunol (2007) 1.80
The sensing of environmental stimuli by follicular dendritic cells promotes immunoglobulin A generation in the gut. Immunity (2010) 1.79
B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells. J Exp Med (2011) 1.78
IkappaBzeta regulates T(H)17 development by cooperating with ROR nuclear receptors. Nature (2010) 1.76
Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol (2011) 1.74
RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development (2010) 1.72
AID: how does it aid antibody diversity? Immunity (2004) 1.71
Role of AID in tumorigenesis. Adv Immunol (2007) 1.69
Learning and memory deficits in Notch mutant mice. Curr Biol (2003) 1.68
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol (2011) 1.64
Apex2 is required for efficient somatic hypermutation but not for class switch recombination of immunoglobulin genes. Int Immunol (2009) 1.62
Inhibition of Notch/RBP-J signaling induces hair cell formation in neonate mouse cochleas. J Mol Med (Berl) (2005) 1.61
Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood (2010) 1.60
Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J Immunol (2002) 1.55
The interleukin-4 enhancer CNS-2 is regulated by Notch signals and controls initial expression in NKT cells and memory-type CD4 T cells. Immunity (2006) 1.53
Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A (2008) 1.49
Multiple roles of Notch signaling in cochlear development. Dev Biol (2007) 1.48
Notch/RBP-J signaling regulates epidermis/hair fate determination of hair follicular stem cells. Curr Biol (2003) 1.46
Recombination signal sequence-binding protein Jkappa alters mesodermal cell fate decisions by suppressing cardiomyogenesis. Proc Natl Acad Sci U S A (2003) 1.45
De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. Proc Natl Acad Sci U S A (2003) 1.43
B cell-specific and stimulation-responsive enhancers derepress Aicda by overcoming the effects of silencers. Nat Immunol (2009) 1.41
Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology (2008) 1.37
AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. J Exp Med (2007) 1.37
Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut (2011) 1.33
Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci U S A (2006) 1.30
Histone3 lysine4 trimethylation regulated by the facilitates chromatin transcription complex is critical for DNA cleavage in class switch recombination. Proc Natl Acad Sci U S A (2010) 1.30
Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. Cell Metab (2006) 1.28
Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci (2003) 1.28
Cartilage-specific RBPjκ-dependent and -independent Notch signals regulate cartilage and bone development. Development (2012) 1.28
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol (2003) 1.26
Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes. Proc Natl Acad Sci U S A (2012) 1.26
Type two hyper-IgM syndrome caused by mutation in activation-induced cytidine deaminase. J Med Dent Sci (2003) 1.25
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood (2008) 1.19
TRIM28 prevents autoinflammatory T cell development in vivo. Nat Immunol (2012) 1.19
The C-terminal region of activation-induced cytidine deaminase is responsible for a recombination function other than DNA cleavage in class switch recombination. Proc Natl Acad Sci U S A (2009) 1.18
Intestinal IgA synthesis: a primitive form of adaptive immunity that regulates microbial communities in the gut. Semin Immunol (2006) 1.16
Activation-induced cytidine deaminase (AID) promotes B cell lymphomagenesis in Emu-cmyc transgenic mice. Proc Natl Acad Sci U S A (2007) 1.15
Adenovirus-mediated gene delivery and in vitro microinsemination produce offspring from infertile male mice. Proc Natl Acad Sci U S A (2002) 1.15
Evolution of class switch recombination function in fish activation-induced cytidine deaminase, AID. Int Immunol (2005) 1.15
Chemokine-dependent T cell migration requires aquaporin-3-mediated hydrogen peroxide uptake. J Exp Med (2012) 1.15
Requirement of non-canonical activity of uracil DNA glycosylase for class switch recombination. J Biol Chem (2006) 1.15